Found 7 matching trials
Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients PHASE4 The primary objective is to demonstrate the non-inferiority at six months o...
Show More Location
Investigational Site Number 204
Learn More & Join Trial
Evaluation of Insulin Glulisine (GP40321) Compared to Insulin Glulisine (Apidra® SoloStar®) in Type 1 Diabetes Mellitus Patients PHASE3 The goal of this clinical trial is to demonstrate the non-inferior immunoge...
Show More Location
RZD-Medicine Clinical Hospital of Chelyabinsk
Learn More & Join Trial
Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients PHASE3 Primary Objective:
\- To compare lixisenatide versus insulin glulisine in ...
Show More Location
Investigational Site Number 840043
Learn More & Join Trial
Better Acceptance of Single Injection Apidra Added to Once Daily Lantus Versus Twice Daily Premixed Insulin in Real Life Use Setting PHASE4 Primary Objective:
To demonstrate non-inferiority of once daily injection ...
Show More Location
Sanofi-Aventis Administrative Office
Learn More & Join Trial
Comparison on Efficacy and Safety of Three Inpatient Insulin Therapy in Type2 DM NA Purpose: To compare efficacy and safety of traditional sliding scale insuli...
Show More Location
the department of internal medicine, Cairo University teaching hospitals,
Learn More & Join Trial
A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus PHASE1 Primary Objective:
To demonstrate bioequivalence between insulin glulisine...
Show More Location
Investigational Site Number 276001
Learn More & Join Trial
Insulin Glargine for Diabetes Metabolism(DM)Type II Patients Under Enteral Nutrition PHASE4 Primary Objective:
1- Proportion of patients with mean daily glycemia \<14...
Show More Location
Sanofi-Aventis Investigational Site Number 076-007
Learn More & Join Trial